Related Experiment Videos
Treatment of status migrainosus
1Anesthesiology & Neurology Department, Multidisciplinary Headache Cliniic, Pittsburgh, PA, USA. dawnpainmd@yahoo.com
Expert Opinion on Pharmacotherapy
|May 5, 2001
Summary
Status migrainosus, defined as migraine lasting over 3 days, traditionally required hospitalization. Newer migraine-specific medications like dihydroergotamine and triptans have improved treatment outcomes, reducing the need for hospital stays.
Area of Science:
- Neurology
- Pharmacology
Background:
- Status migrainosus is defined as migraine episodes persisting for at least 3 days despite treatment.
- Historically, prolonged migraine attacks necessitated inpatient hospitalizations for intravenous medication administration.
- The total disability from status migrainosus includes both the migraine duration and hospitalization period.
Purpose of the Study:
- To review the impact of newer migraine-specific medications on the management of status migrainosus.
- To assess the reduction in prolonged headache episodes and hospitalizations due to targeted therapies.
Main Methods:
- Review of traditional treatment approaches for status migrainosus.
- Analysis of the efficacy of dihydroergotamine and triptans in managing persistent migraine.
- Evaluation of the impact of these medications on hospitalization rates and treatment response.
Main Results:
- Development of targeted migraine therapies, including dihydroergotamine and triptans, has been significant.
- These medications have demonstrated efficacy in treating migraine episodes that previously persisted.
- A reduction in the number of headache episodes requiring extended treatment or hospitalization has been observed.
Conclusions:
- Migraine-specific medications have improved the management of status migrainosus.
- Targeted therapies have reduced the duration of disability and the need for inpatient treatment.
- Advancements in pharmacotherapy offer better outcomes for patients experiencing prolonged migraine attacks.